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Abstract
Craniopharyngiomas are rare epithelial tumours arising along the path of the
craniopharyngeal duct. Two major histological subtypes have been recognised,
the papillary and the adamantinomatous. Craniopharyngiomas remain
challenging tumours to manage and are associated with significant morbidities
and mortality. Recent advances in the molecular pathology of these neoplasms
have identified  mutations in the papillary variant, offering promisingBRAF 
options for targeted pharmacological treatment. The involvement of β-catenin
and the Wnt pathway in the tumorigenesis of the adamantinomatous subtype
has been previously established with the identification of stabilising mutations
in exon 3 of  . Further understanding of the pathogenesis of thisCTNNB1
subtype has been facilitated with the use of mouse models and xenograft
experiments. It has been proposed that the clusters of cells with upregulated
Wnt/β-catenin signalling induce tumour formation in a paracrine manner; the
complex interactions occurring between different cell populations need to be
further clarified for further expansion of this hypothesis. This review outlines
recent key advances in our understanding of the molecular pathology of
craniopharyngiomas and discusses some of the challenges that need to be
overcome for the development of targeted therapies that will hopefully improve
the management and the outcomes of these patients.
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Introduction
Craniopharyngiomas (CPs) are epithelial tumours (WHO grade I) 
arising along the path of the craniopharyngeal duct (embryo-
nal structure connecting stomodeal ectoderm and the evaginated 
Rathke’s pouch). Recent epidemiological data suggest incidence 
rates of 0.17–0.2 cases per 100,000 people1–4. They show a bimo-
dal age distribution with peak incidence rates in children aged 
5–14 and adults aged 50–745. No gender differences have been 
reported3,4.
Histologically, two primary subtypes have been recognised, the 
adamantinomatous (aCP) and the papillary (pCP). The aCP is the 
most common and macroscopically shows cystic and/or solid com-
ponents, necrotic debris, fibrous tissue, and calcification (especially 
common in children). The margins of aCP are sharp and irregu-
lar, often making the identification of the surgical planes difficult. 
The cytoarchitecture of aCP comprises a palisaded basal layer of 
small cells; above this, there is an intermediate layer of variable 
thickness composed of loose aggregates of stellate cells (termed 
“stellate reticulum”) and a top layer facing into the cyst lumen 
with abruptly enlarged, flattened, and keratinised flat plate-like 
squamous cells. The flat squames are desquamated singly or in 
distinctive stacked clusters, forming nodules of wet keratin, often 
heavily calcified and apparent grossly as white flecks5,6. The pCP 
has almost exclusively been described in adults (14–50% of adult 
cases and only up to 2% in children). Macroscopically, it tends 
to be solid or mixed with cystic and solid components, calcifica-
tion is rare, and the cyst content is usually viscous and yellow. It 
is generally well circumscribed, and infiltration of adjacent brain 
tissue by neoplastic epithelium is less frequent than in aCP or 
even absent. Microscopically, it is composed of mature squamous 
epithelium forming pseudopapillae and of an anastomosing 
fibrovascular stroma without the presence of peripheral palisading 
of cells or stellate reticulum5,6.
The optimal management of CPs remains challenging, and the 
main options include surgery combined or not with radiotherapy; 
nonetheless, they can show aggressive and unpredictable behaviour 
with recurrence(s) difficult to treat7. Furthermore, these tumours 
are associated with significant long-term morbidity (mainly 
involving endocrine, visual, hypothalamic, neurobehavioural, and 
cognitive sequelae) and mortality, attributed to the damage of 
critical structures by the primary or recurrent tumour and/or to the 
adverse effects of therapeutic interventions8–11.
Better understanding of the molecular pathology of CPs is of 
major importance for the development of targeted therapies 
aiming to improve the outcomes of these patients. In recent 
years, there have been significant advances in this field, and we 
summarise them in this brief review.
Mutations in BRAF are characteristic for pCP, while 
aCP is associated with CTNNB1 mutations
The involvement of β-catenin and the Wnt pathway in the tumori-
genesis of aCP has been established, since stabilising mutations 
in exon 3 of CTNNB1 that prevent phosphorylation and degrada-
tion of β-catenin have been identified in aCPs12. However, until 
recently, the genetic event underlying the development of pCP 
had remained unclear. Several studies employing whole exome 
sequencing, next-generation panel sequencing, pyrosequencing, 
and Sanger sequencing have demonstrated the presence of acti-
vating mutations in BRAF (V600E) in pCPs. Their reported 
prevalence varies according to the sequencing method used and 
ranges from 81 to 100%13–16. Extensive analysis of aCPs using the 
same methods has not identified recurrent mutations other than 
those in exon 3 of CTNNB113–15. The lack of genetic complexity 
seen in these tumours is typical of their benign behaviour, and 
the almost-perfect segregation of mutation with tumour variant16 
coupled with the existence of a BRAF V600E mutation-specific 
antibody (VE1) provides a useful diagnostic tool for specimens 
with scant epithelium or where diagnosis is challenging; it 
should be noted that there is some concern about the specificity 
of this antibody in pituitary tissue, necessitating cautious interpre-
tation17–19. Much more promising, however, is the possibility for  
targeted pharmacological treatment with agents directed against the 
BRAF (V600E) mutation.
BRAF (V600E) mutations offer the possibility for 
targeted pharmacological treatment
The finding that most pCPs harbour a BRAF (V600E) mutation 
has opened up the exciting possibility of repurposing existing 
drugs for the treatment of pCP cases refractory to surgery and 
radiotherapy. Pharmacological agents that specifically target and 
inhibit mutant BRAF (V600E) are very effective in malignant 
tumours positive for this mutation. Although the development of 
resistance to these agents is a potential drawback, the addition of 
other inhibitors of the MAPK pathway (e.g. trametinib, which 
inhibits MEK) can increase their efficacy20 and reduce the risk of 
cutaneous squamous-cell carcinoma, a common complication of 
BRAF inhibitor treatment.
Two recent reports have shown significant reduction in tumour 
volume in cases of treatment-refractory pCP. Aylwin and 
colleagues21 described a patient with progressive visual dete-
rioration due to a recurrent pCP previously managed with three 
surgeries and fractionated radiotherapy. The tumour harboured 
BRAF (V600E) mutation and the patient was treated with vemu-
rafenib. Stabilisation of vision was achieved within two weeks, 
along with a dramatic reduction in tumour size. Near-complete 
radiological remission occurred after three months, but the patient 
developed cerebrospinal fluid leak, pneumocephalus, and men-
ingitis, necessitating antimicrobial therapy and surgical repair. 
Treatment was interrupted after three months, but the CP recurred 
within six weeks and vemurafenib was restarted. Tumour growth 
was stabilised until seven months after treatment initiation when 
progressive regrowth was detected. The second report from 
Brastianos and colleagues22 described a patient with multiply 
recurrent pCP with BRAF (V600E mutation). Four surgical decom-
pressions were unsuccessful at controlling the growth of the 
tumour, which had a large cystic component. The patient suffered 
bilateral optic neuropathy and panhypopituitarism. Treatment 
was initially dabrafenib monotherapy, and after 17 days the solid 
and cystic components decreased by 50% and 70%, respectively. 
At day 21, the MEK inhibitor trametinib was added for a further 
14 days to reduce the likelihood of resistance to BRAF inhibi-
tion. This regime led to solid and cystic components of the tumour 
Page 3 of 9
F1000Research 2017, 6(F1000 Faculty Rev):1202 Last updated: 24 JUL 2017
decreasing in total by 85% and 81%, respectively. Subsequently, the 
patient underwent endoscopic transsphenoidal resection followed 
by radiotherapy and has remained symptom free 18 months after 
radiation.
Both cases illustrate the promising potential for the use of BRAF 
(V600E) inhibitors and remain to be validated with clinical trials.
aCP and pCP have different epigenomic and 
transcriptional signatures
As well as their genetic differences, CP variants have been shown to 
have different epigenomic and transcriptomic signatures. Analysis 
of the most variably methylated CpG sites by both unsupervised 
hierarchical clustering and principal component analysis identified 
two distinct methylation clusters that separated aCP and pCP15. 
Additionally, unsupervised consensus clustering using the most var-
iably expressed genes identified by microarray analysis resulted in 
clear separation of the two subtypes, indicating that they likely have 
distinct gene expression signatures15,23. Analysis of mRNA expres-
sion demonstrated up-regulation of Wnt/β-catenin pathway targets 
in aCP (LEF1 and AXIN2) and also components of the hedgehog 
signalling pathway (GLI2, PTCH1, and SHH). Additionally, the 
stem cell marker PROM1 (encoding CD133) was overexpressed. 
These findings are in keeping with previous published data from the 
same group that suggest the activation of Wnt and sonic hedgehog 
(SHH) pathways in the cell clusters of aCP (see below)24–28. For a 
detailed discussion of the opportunities for therapy targeting these 
upregulated pathways, see 29.
Interestingly, neither the methylation nor the mRNA expression 
signatures of paediatric aCP and adult aCP separated when ana-
lysed as described above, suggesting that they may not be distinct 
at the epigenomic or transcriptional level15.
Cluster cells have a functional role in the promotion 
of invasion
The cells that accumulate β-catenin in aCP are small in number 
and often, but not always, accumulate to form small clusters with 
a whorl-like pattern near the infiltrating edges of the tumour26,30–35. 
The function of these cluster cells remains enigmatic, but they repre-
sent a population strikingly different from the bulk of the tumour.
A mouse model of aCP demonstrated that CTNNB1 mutation in 
Rathke’s pouch progenitor cells is sufficient to drive aCP tum-
origenesis. Expression of CTNNB1 lacking exon 3 (degradation-
resistant β-catenin) under the control of Hesx1 in the early stages 
of mouse pituitary development results in the formation of tumours 
that closely resemble human aCP, although they lack some of the 
regressive changes seen in the human tumour, e.g. wet keratin. 
Mutation of β-catenin in undifferentiated Rathke’s pouch progeni-
tors is sufficient to drive tumorigenesis of aCP, but once lineage 
commitment has occurred, the mutation is no longer tumorigenic36. 
Interestingly, although CTNNB1 mutation was present in the whole 
population of progenitor cells, there was only cytosolic and/or 
nuclear accumulation of β-catenin in the characteristic cell clusters 
near the invading tumour edge36, indicating that an event other than 
CTNNB1 mutation determined which cells formed clusters.
Hölsken et al. harvested cluster cells from human aCP using laser 
capture microdissection and sought to determine whether they har-
boured an activating mutation in exon 3 of the β-catenin gene and 
whether the Wnt pathway was activated by quantifying Axin2 and 
BMP4. The cluster cells expressed mutated CTNNB1, along with 
the surrounding tumour cells, but only the cluster cells expressed 
elevated levels of Axin2 and BMP4 RNA and protein. The authors 
concluded that CTNNB1 mutation is not sufficient to drive nuclear 
β-catenin accumulation26. These cluster cells were also found 
to express Fascin, a Wnt target gene with a role in cytoskeletal 
organisation and cell migration24,26. Downregulation of both 
β-catenin and fascin expression in human primary aCP tumour 
cells using siRNA impaired their motility and migrational 
capacity24. The study did not separate cells derived from differ-
ent features of the aCP prior to culture, so the culture was likely 
to contain non-cluster cells as well as the cluster cells the authors 
sought to characterise. Mutation in CTNNB1 was present in 
66% of aCPs, but its effect on the behaviour of the cells was not 
explored24. However, the observation that siRNA-mediated down-
regulation of β-catenin or fascin impairs motility in primary human 
aCP cells suggests a potential role for β-catenin, fascin, and (by 
inference) the cluster cells in the invasion into surrounding brain. 
Additionally, the same group demonstrated that claudin, a tight-
junction component, was expressed in the finger-like protrusions 
of aCP but was absent from the cell clusters; this pattern of expres-
sion is consistent with a migratory phenotype for the cluster cells. 
Furthermore, inhibition of claudin expression increased signifi-
cantly the motility of aCP tumour cells, and claudin expression was 
significantly lower in invasive than in non-invasive aCPs27.
Further insight into the role of cluster cells in the pathogenesis of 
aCP was provided in a study by Stache et al., who used a xenotrans-
plant model of human aCP in immunodeficient mice. Serial sec-
tioning of a whole aCP xenograft provided a reconstruction of the 
formation of the finger-like protrusions that invade surrounding 
brain. From these serial sections, the authors inferred that the clus-
ter cells themselves extrude through the palisading epithelial layer 
that encases the tumour to infiltrate the surrounding brain and then 
become enclosed again by a palisading epithelial layer to form the 
whorls characteristic of the finger-like protrusions of aCP. Con-
sistent with this model for infiltration, the xenografts and human 
tumour specimens showed increased proliferation of the palisading 
cells and expression of p21WAF/Cip1 in the cluster cells, indicating cell 
cycle arrest. Although this model is a snapshot of the developing 
aCP and not a time course, the mechanism proposed is an attrac-
tive explanation for both the motile and the quiescent phenotype 
of cluster cells as well as their sustained presence in the infiltrating 
tumour projections.
Pituitary stem cells have a paracrine role in the 
pathogenesis of aCP
The cluster cells in aCP are a clearly distinct subpopulation, but 
their function within the tumour is not yet well understood. There 
is growing evidence for a population of anterior pituitary stem 
cells expressing Sox2 that can give rise to the main anterior pitui-
tary progenitor cell lineages and that, crucially, also have tumour-
inducing potential30,36. Andoniadou et al. created a mouse model 
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that expresses degradation-resistant β-catenin in Sox2+ cells upon 
tamoxifen induction to determine whether these cells could give 
rise to tumours at the embryonic stage and also in adult mice. The 
embryonic-induced mice developed tumours similar to those seen 
in the Hesx1 model36, with identifiable β-catenin-accumulating 
cluster cells reminiscent of those in human aCP that were quiescent 
or slow-dividing (did not express Ki-67) and were undifferentiated 
(did not express lineage commitment markers αGSU and PIT1)37. 
In the adult-induced model, the pattern of β-catenin expression 
was more complex, with some cells showing nucleocytoplasmic 
accumulation.
Lineage tracing experiments used Sox2+ cells simultaneously 
expressing both degradation-resistant β-catenin and yellow 
fluorescent protein (YFP) aiming to identify both these tumour 
progenitor cells and their descendants37. Interestingly, after induc-
tion of degradation-resistant β-catenin, the majority of tumour cells 
formed did not express YFP. However, there were populations of 
YFP-expressing cells adjacent to the tumour cells, some of which 
formed clusters. These findings indicate that the tumour cells were 
not derived from Sox2+ cells expressing degradation-resistant 
β-catenin. However, nucleocytoplasmic accumulation of β-catenin 
was observed in tumour cells that did not express YFP (and so 
were not derived from the Sox2+ progenitor cells), suggesting that 
this accumulation and activation of the Wnt pathway is non- 
cell-autonomous and may occur as a result of signalling from 
the adjacent Sox2+ cell population. Indeed, the β-catenin- 
accumulating, YFP– tumour cells were often found in close 
proximity to the YFP+ cells, suggesting a functional relationship37.
Expression of degradation-resistant β-catenin in Sox2+ cells leads 
to the formation of β-catenin-accumulating cell clusters that 
resemble those in human aCP, implicating Sox2+ progenitor cells 
as the cells in which the tumour-initiating mutation in β-catenin 
occurs. However, these cells do not give rise in an autonomous 
manner to the tumour cells as would be expected if they were 
true mutation-sustaining cancer stem cells. Instead, they appear 
to drive tumour formation in a paracrine manner by inducing 
tumorigenic events in adjacent cells. The authors propose that 
induction of degradation-resistant β-catenin initiates a brief period 
of proliferation in a proportion of Sox2+ cells. The resulting 
daughter cells then form the β-catenin-accumulating clusters that 
are characteristic of aCP. These clusters become quiescent and 
secretory, signalling by means of secretory proteins including 
members of the fibroblast growth factor (FGF), transforming 
growth factor beta (TGFβ), epithelial growth factor, and SHH 
pathways, along with pro-inflammatory cytokines and chemok-
ines,30 to induce transformation in surrounding cells and perhaps 
modify the tumour microenvironment. It is these non-Sox2+- 
derived cells that form the bulk of the tumour37.
The mouse paracrine model of aCP pathogenesis includes a 
stem-cell-like progenitor that sustains the oncogenic mutation 
but is not the cell-of-origin of the tumour (comprehensively 
reviewed in 38–40). There is considerable evidence to suggest that 
human aCP may follow the same pathogenic route. The cluster 
cells of human aCP are non-proliferative and express members of 
the FGF, TGFβ, and SHH pathways25,26,30, and they are also non- 
proliferative and undifferentiated36,41. A representation of the dif-
ferent cell populations at the invading edge of aCP and some of 
the differentially expressed proteins and factors is shown in 
Figure 1. The tumour environment is a competitive one in which 
more proliferative cells will out-compete and replace their more 
indolent neighbours in a process termed somatic or clonal evolu-
tion (extensively reviewed in 42). This concept generally refers 
to aggressive tumours with a high degree of genetic inhomogene-
ity, in which particular mutations may confer survival advantages 
to subpopulations of cells, but it seems reasonable that, even in a 
tumour with a limited mutational landscape, a quiescent population 
of cells would quickly be replaced by proliferating cells unless they 
were performing a function essential for the pathogenesis of the 
tumour, as has been proposed by other authors38,40. Instead, even 
in highly invasive and destructive aCPs that destroy surrounding 
hypothalamic and pituitary tissue, clusters of β-catenin-accumulat-
ing, quiescent cells remain. Furthermore, these clusters are often 
located near to the invading tumour periphery, in regions where 
the proliferation of surrounding cells is high and selective pres-
sure is likely to be significant. Reports differ as to the prevalence of 
CTNNB1 mutation in aCPs and sequencing of a bulk aCP tumour 
is likely to result in false negative results if the mutation is present 
only in cluster cells, which may constitute a small proportion of the 
bulk tumour and so fall below the limit of detection of the method 
employed. However, immunohistochemical studies have suggested 
that even in aCP with no obvious cell clusters, there are β-catenin-
accumulating cells found distributed throughout the tumour35. This 
is useful from a diagnostic perspective but may also be indicative 
of the importance of these cells for tumour pathogenesis. Further 
experiments will be required to determine whether cluster cells are 
essential paracrine signalling hubs for tumour pathogenesis after 
the tumour-initiating mutation in CTNNB1, but the current available 
evidence is consistent with this model.
Mouse models, primary cell culture, and xenografts 
offer opportunities to study aCP pathogenesis
Mouse models, primary cell cultures, and xenograft models are 
valuable tools for studying the pathogenesis of aCP, each of which 
has advantages for answering particular questions; however, none 
fully recapitulates the features of the human tumour. The mouse 
models (both Hesx1- and Sox2-driven36,37), while they allow the 
study and manipulation of tumorigenesis, lack some features of 
human aCP: for instance, they do not develop a defined palisad-
ing layer of epithelial cells at the invading edge of the tumour, nor 
do they show calcification or the anucleated ghost cells (wet kera-
tin) that are pathognomonic for human aCP. It has been suggested 
that wet keratin is a feature of a more mature tumour and that the 
lack of this feature in the mouse models is likely a consequence of 
the relatively short period (weeks) over which the mouse tumour 
develops. A report by Scagliotti et al.43 of an intrauterine-diagnosed 
congenital aCP at 23 weeks of gestation described the presence of 
wet keratin and calcium deposits in the tumour. This is comparable 
to the 2–5-month period over which the Sox2+ aCP mouse model 
develops37, so perhaps the lack of wet keratin and calcification 
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Figure 1. Subpopulations of cells at the invading edge of adamantinomatous craniopharyngioma. The relative expression of various 
targets and activity of signalling pathways vary according to cell type. BMP, bone morphogenetic protein; FGF, fibroblast growth factor; SHH, 
sonic hedgehog.
in the mouse tumour is due to species-specific differences in the 
pathogenesis of this tumour or perhaps the mouse model is lacking 
a facet of the human tumour that is not yet identified.
Primary human aCP cell cultures24 have the advantage of being 
derived from the human tumour and can be used to screen phar-
macological agents relatively easily; however, the process of tis-
sue disruption required for cell culture means that the complex 
architecture of the aCP is lost. Any functional relationship between 
the cluster cells and surrounding tumour is likely to be perturbed 
or destroyed. Furthermore, culture conditions cannot replicate 
microenvironmental signals to the tumour from surrounding tissue. 
It has not been tested whether aCP primary cells in culture develop 
cluster-like formations and the cultures have not been molecu-
larly profiled. Greater characterisation of this model is needed to 
determine the extent of its utility in studies of human aCP.
Xenograft models28 preserve the cytoarchitecture of the human aCP 
and provide a microenvironmental context (albeit from a different 
species) in which the aCP can grow and invade. However, oppor-
tunities for the manipulation of tumour pathogenesis are limited in 
this model, and its suitability for testing pharmacological agents 
may be compromised by the low availability of human tumour 
material and differences in responses to agents between species.
All the models discussed here have provided greater insight into the 
pathogenesis of aCP and represent useful tools for answering out-
standing questions, but the particular advantages and disadvantages 
of each must be acknowledged and considered.
Heterogeneity of aCP represents a challenge to the 
development of pharmacological treatment
This review has highlighted the very different architecture and 
pathogenesis of CP variants. While the discovery of the BRAF 
(V600E) mutation in pCP has afforded us an opportunity for a 
promising pharmacological intervention, recent progress in under-
standing aCP reveals a morphologically complex tumour with 
distinct cell populations that have differing functions and cells of 
origin. If the paracrine model for aCP tumorigenesis withstands 
further investigation, it presents a potential target for therapeu-
tic intervention, namely the cluster cells that initiate and support 
tumorigenesis in surrounding cells. However, the stem-like proper-
ties of these cells make them difficult targets for cytotoxic agents, 
which are often ineffective against quiescent cells. Any targeted 
Page 6 of 9
F1000Research 2017, 6(F1000 Faculty Rev):1202 Last updated: 24 JUL 2017
therapy aimed at disrupting the paracrine signalling between 
clusters and surrounding cells will require deeper understanding of 
the signalling events and the effect on the surrounding tumour.
Conclusions
Understanding of CP pathogenesis has increased considerably in 
recent years. The identification of BRAF (V600E) mutations in pCP 
has led to the potential for new targeted pharmacological therapy. 
Our understanding of aCP has been greatly improved by mouse 
model and xenograft experiments revealing new and critical roles 
for β-catenin-accumulating cluster cells; however, there is still 
much to clarify about the complex interactions that occur between 
different cell populations within this neoplasm before we are in the 
position to develop effective targeted therapies.
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